Related Experiment Video
Updated: Feb 7, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Crosstalk between PKCα and PI3K/AKT Signaling Is Tumor Suppressive in the Endometrium
Alice H Hsu1, Michelle A Lum1, Kang-Sup Shim2
1Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Abstract:
Protein kinase C (PKC) isozymes are commonly recognized as oncoproteins based on their activation by tumor-promoting phorbol esters. However, accumulating evidence indicates that PKCs can be inhibitory in some cancers, with recent findings propelling a shift in focus to understanding tumor suppressive functions of these enzymes. Here, we report that PKCα acts as a tumor suppressor in PI3K/AKT-driven endometrial cancer. Transcriptional suppression of PKCα is observed in human endometrial tumors in association with aggressive disease and poor prognosis. In murine models, loss of PKCα is rate limiting for endometrial tumor initiation. PKCα tumor suppression involves PP2A-family-dependent inactivation of AKT, which can occur even in the context of genetic hyperactivation of PI3K/AKT signaling by coincident mutations in PTEN, PIK3CA, and/or PIK3R1. Together, our data point to PKCα as a crucial tumor suppressor in the endometrium, with deregulation of a PKCα→PP2A/PP2A-like phosphatase signaling axis contributing to robust AKT activation and enhanced endometrial tumorigenesis.
Insights
Protein Kinase C alpha (PKCα) suppresses endometrial tumors by inhibiting AKT signaling. Loss of PKCα promotes aggressive cancer, highlighting its tumor-suppressive role.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- Protein Kinase C (PKC) isozymes are often viewed as oncoproteins.
- Emerging evidence suggests PKC can act as a tumor suppressor in certain cancers.
- This study investigates the role of PKCα in endometrial cancer.
Purpose of the Study:
- To determine if PKCα functions as a tumor suppressor in PI3K/AKT-driven endometrial cancer.
- To investigate the molecular mechanisms underlying PKCα's tumor suppressive activity.
- To explore the clinical relevance of PKCα expression in endometrial tumors.
Main Methods:
- Analysis of human endometrial tumor data for PKCα expression.
- Utilized murine models to study the effects of PKCα loss on tumor initiation.
- Investigated the signaling pathways affected by PKCα, including AKT and PP2A.
Main Results:
- PKCα acts as a tumor suppressor in PI3K/AKT-driven endometrial cancer.
- Transcriptional suppression of PKCα correlates with aggressive disease and poor prognosis.
- Loss of PKCα is critical for endometrial tumor initiation in preclinical models.
- PKCα suppresses tumors via PP2A-dependent inactivation of AKT, even with PI3K/AKT pathway mutations.
Conclusions:
- PKCα is a critical tumor suppressor in the endometrium.
- Deregulation of the PKCα→PP2A signaling axis contributes to endometrial tumorigenesis.
- Targeting this pathway may offer therapeutic strategies for endometrial cancer.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
Endocrine Signaling
Bacterial Signaling
Yeast Signaling
What is Cell Signaling?
Paracrine Signaling

